Signant’s SmartSignals RTSM solution helped an innovative biopharmaceutical company secure an FDA Orphan Drug designation for its cardiomyopathy drug.

The protocol required an RTSM system that could accommodate numerous cohorts, each with varying drug combinations and visit schedules. The set-up team studied the protocol, developed the complex on-site titration, dispensation, and scheduling logic, then articulated its design to the customer.

Learn more about how Signant’s SmartSignals RTSM solution enabled seamless transition of eligible patients from Phase II to Phase III, and provided the client with timely information about patient dosing and inventory levels.